A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (Anti?pd-l1 antibody) IN patients with UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (Anti?pd-l1 antibody) IN patients with UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER